Andreas Kaubisch

4.6k total citations
66 papers, 1.3k citations indexed

About

Andreas Kaubisch is a scholar working on Oncology, Hepatology and Molecular Biology. According to data from OpenAlex, Andreas Kaubisch has authored 66 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 22 papers in Hepatology and 17 papers in Molecular Biology. Recurrent topics in Andreas Kaubisch's work include Hepatocellular Carcinoma Treatment and Prognosis (21 papers), Cancer Treatment and Pharmacology (15 papers) and Colorectal Cancer Treatments and Studies (14 papers). Andreas Kaubisch is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (21 papers), Cancer Treatment and Pharmacology (15 papers) and Colorectal Cancer Treatments and Studies (14 papers). Andreas Kaubisch collaborates with scholars based in United States, Canada and Australia. Andreas Kaubisch's co-authors include David M. Segal, Pilar Pérez, María Garrido, J A Titus, Sanjay Goel, Lakshmi Rajdev, Charles Hesdorffer, Rui Qin, Nitin Ohri and Maureen Ward and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Andreas Kaubisch

65 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andreas Kaubisch United States 18 584 498 235 226 175 66 1.3k
Kang–Da Liu China 18 302 0.5× 600 1.2× 411 1.7× 139 0.6× 144 0.8× 41 1.2k
Maria Grazia Diodoro Italy 20 436 0.7× 367 0.7× 167 0.7× 131 0.6× 196 1.1× 41 1.1k
Yoshiyasu Nakamura Japan 25 528 0.9× 650 1.3× 161 0.7× 231 1.0× 160 0.9× 71 1.6k
Jane Robertson United Kingdom 22 1.3k 2.2× 816 1.6× 225 1.0× 121 0.5× 174 1.0× 57 2.0k
Jeffrey S. Wiezorek United States 18 1.3k 2.3× 631 1.3× 112 0.5× 166 0.7× 216 1.2× 38 1.7k
Till Krech Germany 28 456 0.8× 795 1.6× 493 2.1× 461 2.0× 141 0.8× 79 1.9k
Stefania Brozzetti Italy 21 468 0.8× 586 1.2× 337 1.4× 343 1.5× 95 0.5× 50 1.6k
H. D. Saeger Germany 22 1.1k 1.8× 815 1.6× 102 0.4× 325 1.4× 95 0.5× 63 2.2k
Carsten Grüllich Germany 25 493 0.8× 557 1.1× 79 0.3× 168 0.7× 264 1.5× 90 1.5k
Collin M. Blakely United States 21 808 1.4× 800 1.6× 448 1.9× 347 1.5× 302 1.7× 75 2.1k

Countries citing papers authored by Andreas Kaubisch

Since Specialization
Citations

This map shows the geographic impact of Andreas Kaubisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Kaubisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Kaubisch more than expected).

Fields of papers citing papers by Andreas Kaubisch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Kaubisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Kaubisch. The network helps show where Andreas Kaubisch may publish in the future.

Co-authorship network of co-authors of Andreas Kaubisch

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Kaubisch. A scholar is included among the top collaborators of Andreas Kaubisch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Kaubisch. Andreas Kaubisch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Desai, Kush, Andreas Kaubisch, Milan Kinkhabwala, et al.. (2024). Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States. Journal of Hepatocellular Carcinoma. Volume 11. 257–269. 5 indexed citations
2.
Sukrithan, Vineeth, Briant Fruth, Rui Qin, et al.. (2023). A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocrine Related Cancer. 30(11). 4 indexed citations
3.
Acuña-Villaorduña, Ana, V. Shankar, Rafi Kabarriti, et al.. (2022). Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma. Cancer Control. 29. 2905552459–2905552459. 2 indexed citations
4.
Lipman, Jeffrey, et al.. (2019). Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?. Seminars in Nuclear Medicine. 49(3). 170–181. 8 indexed citations
5.
Zhang, Yifei, N. Patrik Brodin, Nitin Ohri, et al.. (2019). Association between neutrophil–lymphocyte ratio, socioeconomic status, and ethnic minority with treatment outcome in hepatocellular carcinoma. Hepatology International. 13(5). 609–617. 8 indexed citations
6.
Tang, Justin, Nitin Ohri, Rafi Kabarriti, et al.. (2018). Model for End-Stage Liver Disease and Sodium Velocity Predicts Overall Survival in Nonmetastatic Hepatocellular Carcinoma Patients. Canadian Journal of Gastroenterology and Hepatology. 2018. 1–7. 3 indexed citations
7.
Mehta, Keyur, et al.. (2018). Radiation Recall Dermatitis in Patients Treated with Sorafenib. Case Reports in Oncological Medicine. 2018. 1–3. 8 indexed citations
8.
Kam, Audrey E., Gopichand Pendurti, Umang Shah, et al.. (2018). Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials. Investigational New Drugs. 37(3). 490–497. 6 indexed citations
9.
Rubinstein, Maria M., et al.. (2017). Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation. Journal of Gastrointestinal Oncology. 8(6). 1051–1055. 19 indexed citations
10.
Kaubisch, Andreas, et al.. (2016). Multiple Endocrine and Neoplastic Diseases After Unsuccessful Treatment of Hepatitis C With Interferon and Ribavirin. The American Journal of the Medical Sciences. 354(1). 66–66.
11.
Hobday, Timothy J., Rui Qin, Diane Reidy‐Lagunes, et al.. (2014). Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. Journal of Clinical Oncology. 33(14). 1551–1556. 96 indexed citations
12.
Knox, Jennifer J., Rui Qin, Jonathan Strosberg, et al.. (2014). A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Investigational New Drugs. 33(1). 241–246. 27 indexed citations
13.
Cynamon, Jacob, John F. Reinus, Milan Kinkhabwala, et al.. (2012). Value of Noncontrast CT Immediately after Transarterial Chemoembolization of Hepatocellular Carcinoma with Drug-eluting Beads. Journal of Vascular and Interventional Radiology. 23(8). 1031–1035. 20 indexed citations
14.
Sood, Arjun B., Radhashree Maitra, Raviraja N. Seetharam, et al.. (2012). PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 11(2). 143–150. 78 indexed citations
15.
Wang, Hongwei, Madhukumar Venkatesh, Hao Li, et al.. (2011). Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. Journal of Clinical Investigation. 121(8). 3220–3232. 115 indexed citations
16.
Sparano, Joseph A., Vincent Vinciguerra, Allyson J. Ocean, et al.. (2010). Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma. American Journal of Clinical Oncology. 33(2). 121–124. 36 indexed citations
17.
Goel, Sanjay, Robert J. Bauer, Kavita Desai, et al.. (2007). Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Annals of Oncology. 18(10). 1704–1707. 21 indexed citations
18.
Goel, Sanjay, Kavita Desai, Imran Chaudhary, et al.. (2006). Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. Investigational New Drugs. 25(3). 237–245. 6 indexed citations
19.
20.
Hesdorffer, Charles, Janet Ayello, Maureen Ward, et al.. (1998). Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.. Journal of Clinical Oncology. 16(1). 165–172. 164 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kang–Da Liu Breakdown of academic impact, for papers by Maria Grazia Diodoro Breakdown of academic impact, for papers by Yoshiyasu Nakamura Breakdown of academic impact, for papers by Jane Robertson Breakdown of academic impact, for papers by Jeffrey S. Wiezorek Breakdown of academic impact, for papers by Till Krech Breakdown of academic impact, for papers by Stefania Brozzetti Breakdown of academic impact, for papers by H. D. Saeger Breakdown of academic impact, for papers by Carsten Grüllich Breakdown of academic impact, for papers by Collin M. Blakely
Rankless by CCL
2026